Figure 6
Figure 6. In vivo effects of the combination of nilotinib (15-20 mg/kg) and imatinib (50 mg/kg) on BCR-ABL–expressing cells in a murine leukemia model. (A) Effects of vehicle, nilotinib alone (15 mg/kg), imatinib alone (50 mg/kg), or a combination of nilotinib and imatinib on growth of 32D.p210-luc+ cells in NCR nude mice. Mice were intravenously injected via tail vein with 800 000 cells/mouse (with no prior sublethal irradiation). Images were taken on day 1 and day 8 after intravenous injection. On day 8 after intravenous injection, mice had received a total of 7 days of treatment with vehicle or drug. Mice were killed, weighed, and preserved for histopathologic analysis approximately 7 days after the last imaging day. Photo images show bioluminescence as seen on the last imaging day. (B) Bioluminescence values plotted as percent of baseline for mice treated with vehicle, nilotinib alone (15 mg/kg), imatinib alone (50 mg/kg), or a combination of nilotinib and imatinib. Vehicle (n = 3), nilotinib alone (n = 3), imatinib alone (n = 3), nilotinib + imatinib (n = 3). (C) Percent spleen weights for 32D.p210-luciferase–injected NCR nude mice treated with nilotinib alone (15 mg/kg), imatinib alone (50 mg/kg), or a combination of nilotinib and imatinib. (D) Effects of nilotinib (20 mg/kg) and imatinib (50 mg/kg), alone and combined, on growth of 32D.p210-luc+ cells in NCR nude mice. Mice for this experiment were injected with 32D.p210-luc+ cells via tail-vein injection (with no prior sublethal irradiation). Images were taken on day 1, day 6, day 8, and day 9 after intravenous injection. By day 9 after intravenous injection, mice had received a total of 8 days of treatment with vehicle or drug. Mice were killed and preserved for histopathologic analysis on day 9 after intravenous injection. Photo images show bioluminescence as seen on the last imaging day. (E) Bioluminescence values are plotted as percent of baseline. Vehicle (n = 2), nilotinib only (n = 2), imatinib only (n = 2), nilotinib + imatinib (n = 2). Where shown, error bars indicate SEM.

In vivo effects of the combination of nilotinib (15-20 mg/kg) and imatinib (50 mg/kg) on BCR-ABL–expressing cells in a murine leukemia model. (A) Effects of vehicle, nilotinib alone (15 mg/kg), imatinib alone (50 mg/kg), or a combination of nilotinib and imatinib on growth of 32D.p210-luc+ cells in NCR nude mice. Mice were intravenously injected via tail vein with 800 000 cells/mouse (with no prior sublethal irradiation). Images were taken on day 1 and day 8 after intravenous injection. On day 8 after intravenous injection, mice had received a total of 7 days of treatment with vehicle or drug. Mice were killed, weighed, and preserved for histopathologic analysis approximately 7 days after the last imaging day. Photo images show bioluminescence as seen on the last imaging day. (B) Bioluminescence values plotted as percent of baseline for mice treated with vehicle, nilotinib alone (15 mg/kg), imatinib alone (50 mg/kg), or a combination of nilotinib and imatinib. Vehicle (n = 3), nilotinib alone (n = 3), imatinib alone (n = 3), nilotinib + imatinib (n = 3). (C) Percent spleen weights for 32D.p210-luciferase–injected NCR nude mice treated with nilotinib alone (15 mg/kg), imatinib alone (50 mg/kg), or a combination of nilotinib and imatinib. (D) Effects of nilotinib (20 mg/kg) and imatinib (50 mg/kg), alone and combined, on growth of 32D.p210-luc+ cells in NCR nude mice. Mice for this experiment were injected with 32D.p210-luc+ cells via tail-vein injection (with no prior sublethal irradiation). Images were taken on day 1, day 6, day 8, and day 9 after intravenous injection. By day 9 after intravenous injection, mice had received a total of 8 days of treatment with vehicle or drug. Mice were killed and preserved for histopathologic analysis on day 9 after intravenous injection. Photo images show bioluminescence as seen on the last imaging day. (E) Bioluminescence values are plotted as percent of baseline. Vehicle (n = 2), nilotinib only (n = 2), imatinib only (n = 2), nilotinib + imatinib (n = 2). Where shown, error bars indicate SEM.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal